Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard(London Cancer), Robin Millman(MRC Clinical Trials Unit at UCL), Claire Murphy(University College London), Emma Gray(Wellcome Sanger Institute), Ashwin Sachdeva(University of Manchester), John M. Russell, Carys Thomas(Cancer Research UK), Silke Gillessen(Institute of Oncology Research), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Jacob Tanguay(Velindre Cancer Centre), Adrian Cook(University College London), Laura Murphy(Brigham and Women's Hospital), Angus Robinson(Royal Sussex County Hospital), John Wagstaff(Maastricht University Medical Centre), Anjali Zarkar(Cancer Research UK), Helen Saxby(Torbay and South Devon NHS Foundation Trust), Michael D. Brown(University of Maryland, Baltimore), Narayanan Srihari(Shrewsbury and Telford Hospital NHS Trust), Warren Grant(Cheltenham General Hospital), David P. Dearnaley(Royal Marsden NHS Foundation Trust), Amir Montazeri(Clatterbridge Cancer Centre NHS Foundation Trust), Malcolm D. Mason(Royal Marsden Hospital), William Cross(Leeds Teaching Hospitals NHS Trust), Claire Amos(MRC Clinical Trials Unit at UCL), Clare Gilson(Cancer Research UK), Robert J. Jones(Beatson West of Scotland Cancer Centre), Joe M. O’Sullivan(San Antonio College), Richard Cathomas(Kantonsspital Graubünden), Ian Pedley, Joanna Gale(Queen Alexandra Hospital), Omi Parikh(Royal Blackburn Teaching Hospital), Noel W. Clarke(The Christie NHS Foundation Trust), Nazia Parkar(University College London), Mymoona Alzouebi(Weston Park Cancer Centre), Duncan C. Gilbert(Royal Sussex County Hospital), Cheryl Pugh(MRC Clinical Trials Unit at UCL), Alison Birtle(University of Lancashire), Hannah Rush(University College London), Carmel Pezaro(Royal Marsden NHS Foundation Trust), Alex Hoyle(The Christie NHS Foundation Trust), Chris Brawley(Cancer Research UK), Carlos Díaz-Montaña(University College London), Craig Jones(Cancer Research UK), James Wylie(Cancer Research UK), Zafar Malik(Cancer Research UK), Christopher Parker(Royal Marsden NHS Foundation Trust), Simon Chowdhury(Sarah Cannon Research Institute), Yatin Jain(Salford Royal NHS Foundation Trust), Prantik Das(Royal Derby Hospital)
Cited by 110
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k